Free tool
FAERS Monitor: Tobradex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050616 or its brand name (Tobradex, Dexamethasone, Tobramycin). Reports on generic versions are filed under their own applications.
Reports
3,324
Serious
2,271
68% of reports
Hospitalization
875
Death reported
150
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain243
- off label use226
- drug ineffective184
- vision blurred182
- headache179
- ocular hyperaemia170
- eye irritation169
- nausea168
- fatigue165
- dizziness143
- pain137
- diarrhoea135
- visual impairment122
- dyspnoea121
- anxiety106
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 23 |
| 2006 | 44 |
| 2007 | 30 |
| 2008 | 41 |
| 2009 | 59 |
| 2010 | 58 |
| 2011 | 77 |
| 2012 | 93 |
| 2013 | 74 |
| 2014 | 95 |
| 2015 | 147 |
| 2016 | 201 |
| 2017 | 168 |
| 2018 | 321 |
| 2019 | 268 |
| 2020 | 258 |
| 2021 | 254 |
| 2022 | 241 |
| 2023 | 238 |
| 2024 | 236 |
| 2025 | 200 |
| 2026 | 190 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,835 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 243 | 27.4 | 24.2 | 6,137 |
| ocular hyperaemiaSignal | 170 | 22.7 | 19.6 | 3,508 |
| eye irritationSignal | 169 | 18.6 | 16.1 | 2,801 |
| vision blurredSignal | 182 | 8.4 | 7.3 | 1,185 |
| visual impairmentSignal | 122 | 6.2 | 5.2 | 534 |
| anxietySignal | 106 | 2.4 | 2.0 | 83 |
| dizziness | 143 | 1.8 | 1.5 | 53 |
| headache | 179 | 1.8 | 1.6 | 66 |
| off label use | 226 | 1.6 | 1.4 | 57 |
| pain | 137 | 1.4 | 1.2 | 16 |
| dyspnoea | 121 | 1.4 | 1.1 | 11 |
| nausea | 168 | 1.3 | 1.2 | 15 |
| fatigue | 165 | 1.3 | 1.2 | 15 |
| diarrhoea | 135 | 1.3 | 1.1 | 11 |
| drug ineffective | 184 | 0.9 | 0.8 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.